Apimeds Pharmaceuticals US (APUS) Total Current Liabilities (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Total Current Liabilities for 4 consecutive years, with $21.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 2504.85% year-over-year to $21.1 million; the trailing twelve-month figure through Jun 2026 stood at $21.1 million (up 2504.85% YoY), and the FY2025 full-year result was $10.7 million, up 945.21% from the prior year.
• Total Current Liabilities advanced to $21.1 million in Q2 2026 per APUS's latest filing, from $10.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $21.1 million in Q2 2026 and bottomed at $123316.0 in Q4 2023.
• Historically, Total Current Liabilities has averaged $5.2 million across 4 years, with a median of $1.1 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities jumped 730.66% in 2024, then jumped 2504.85% in 2026.
• Over 4 years, Total Current Liabilities stood at $123316.0 in 2023, then surged by 730.66% to $1.0 million in 2024, then jumped by 945.21% to $10.7 million in 2025, then soared by 96.83% to $21.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $21.1 million, $10.7 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.